Journal of Clinical Oncology
Articles in this Issue
Real-world data on bispecific antibodies (BsAbs) administration in community oncology settings.
e13532 Background: BsAbs represent a transformative advancement in oncology, with 10 FDA-approved agents as of early 2025. Despite their potential, widesp...
Ropeginterferon alfa-2b versus anagrelide for the treatment of essential thrombocythemia: Topline results of the phase 3 SURPASS-ET trial.
6500 Background: BCR::ABL1 -negative myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET), polycythemia vera (PV) and...
Factors associated with choosing hematology/oncology as a career path.
e21026 Background: Limited studies have evaluated the factors that influence medicine trainees’ decisions to pursue hematology/oncology (heme/onc) as a ca...
Racial and ethnic differences in biomarker testing for targetable alterations among patients with HR+ HER2- metastatic breast cancer (mBC).
1084 Background: In recent years novel therapies have been approved for patients (pts) with mBC and ESR1 , AKT1...
Trends in location of death among adolescents and young adults with solid and liquid tumors in the United States.
e13755 Background: The location of death is a vital aspect of end-of-life (EOL) care for adolescent and young adult (AYA) cancer patients, influenced by c...
Evaluating overall survival with abiraterone acetate compared to enzalutamide in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Real-world data from the Flatiron electronic health records database.
e17033 Background: Real-world effectiveness of abiraterone acetate (abi) vs enzalutamide (enza) in chemotherapy-naïve metastatic castration-resistant pros...
Implementing integrated proactive supportive care pathways in oncology: Results from the PROACT-PRO.GNOSIS prospective cohort study.
e24104 Background: Can we limit the decrease of quality of life during anticancer treatments? Early assessment of risk factors and patient needs is centra...
Predictive implications of immune-related adverse events after exposure to VEGF inhibitors on outcomes in patients with advanced NSCLC treated with prior immune check point inhibitor.
8568 Background: Immune-related adverse events (irAEs) have been associated with enhanced antitumor immune activity, potentially correlating with improved...
NeoPancONE: GATA6 expression as a predictor of benefit to peri-operative modified FOLFIRINOX in resectable pancreatic adenocarcinoma (r-PDAC): A multicentre phase II study.
4011 Background: Modified FOLFIRINOX (mFFX) is increasingly used in the perioperative setting in r-PDAC and patients (pts)...
PancreaX: Artificial intelligence–driven diagnosis of pancreatic cancer.
e16465 Background: Pancreatic ductal adenocarcinoma (PDAC) is one of the most lethal malignancies, with poor survival rates largely due to late-stage diag...
Treatment patterns and survival by race among men with metastatic castration-resistant prostate cancer (mCRPC) in the United States: A US electronic medical record database 2020-2023.
e17058 Background: Given the potential shift of androgen receptor pathways (ARPI)/docetaxel use to earlier disease states of metastatic hormone-sensitive...
Predictive modeling based on radiomics and hematological parameters for recurrence-free survival after curative resection in patients with hepatocellular carcinoma.
e16280 Background: Early recurrence following curative resection represents a significant challenge in the management of hepatocellular carcinoma (HCC). I...
Prognostic factors for surgically resected pulmonary large cell neuroendocrine carcinoma: A single-institution real-world experience.
e20033 Background: Pulmonary large cell neuroendocrine carcinoma (LCNEC) is a rare, highly aggressive malignancy with a poor prognosis, accounting for app...
Outcomes of patients with concurrent chronic lymphocytic leukemia and non-small cell lung carcinoma.
e20532 Background: Chronic lymphocytic leukemia (CLL) is the most common type of leukemia and lung carcinoma is the second most common cause of cancer but...
A phase 3 study of 177Lu-rosptamab plus standard of care vs. standard of care alone in patients with metastatic castration-resistant prostate cancer (ProstACT Global).
TPS5126 Background: The treatment of advanced prostate cancer (PC) is challenging, with undesirable side effects that impact patient quality of life. Radi...
Safety and efficacy of ifebemtinib (IN10018) combined with garsorasib (D-1553) in KRAS G12C mutant solid tumors from a phase Ib/II study: Results from single-arm of non-small-cell lung cancer (NSCLC) and randomized part of colorectal cancer (CRC).
8629 Background: RAS inhibitors (RASi) need to be combined with optimal partner(s) to maximize their efficacy. Ifebemtinib (ifebe) is a highly potent and...
Evaluating the cost-effectiveness of genetic testing in high-risk families with confirmed germline cancer mutations.
e23164 Background: First-degree relatives (FDRs) of cancer patients with hereditary mutations may benefit from germline genetic testing, enabling early in...
Pulmonary toxicities in patients (pts) with metastatic breast cancer (mBC) treated with trastuzumab deruxtecan (T-DXd): The Mayo Clinic Enterprise Experience, updated.
1089 Background: T-DXd has become an important treatment option in mBC and other malignancies. Interstitial lung disease/pneumonitis (ILD) occurred in 10-...
Real-world analyses to evaluate the role of TIGIT as a target in first-line (1L) gastric, gastroesophageal junction, and esophageal adenocarcinomas (GC/GEJC/EAC).
4033 Background: Anti-programmed death protein 1 (PD-1) immune checkpoint inhibitors (ICIs) are approved for GC/GEJC/EAC.T-cell immunoreceptor with Ig and...
Chemotherapy-induced modulation of brain glucose metabolism in leukemia patients: A retrospective comparative study.
e18572 Background: Chemotherapy-induced cognitive impairment, or "chemo brain," is characterized by memory deficits, emotional disturbance, and impaired e...
Clinical outcomes of first-line immune checkpoint inhibitors with chemotherapy in advanced EBV-associated gastric cancer.
4049 Background: EBV-associated gastric cancer (EBVaGC) is a distinct subgroup of GC with high PD-L1/PD-L2 expression and immune cell infiltration. While...
Association between benign cardiac tumors and thromboembolic events: Analysis of the 2018-2022 National Inpatient Sample.
e24008 Background: Benign cardiac tumors, while rare, represent significant cardiac neoplasms with potential thromboembolic complications. Despite their c...
Vilastobart (XTX101), a tumor-activated, Fc-enhanced anti–CTLA-4 monoclonal antibody, in combination with atezolizumab in patients with MSS CRC.
3553 Background: Vilastobart (XTX101) is tumor-activated, high affinity, Fc-enhanced aCTLA-4 designed to focus activity toward the tumor and minimize syst...
Pembrolizumab vs chemotherapy in elderly patients with NSCLC: A comparative analysis of survival and adverse effects.
e20528 Background: Elderly patients with non-small cell lung cancer (NSCLC) require treatment strategies that balance efficacy and tolerability. Immunothe...
Clinical and radiometabolic correlatives of ddPCR liquid biopsy for BRAF V600 mutated melanoma.
e15046 Background: BRAF V600 is the most common driver mutation in melanoma, seen in ≈50% of patients. Recently, the use of liquid biopsy assays that are...